Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin dose comparison to lower testosterone and improve metabolic status in postmenopausal women treated for breast cancer
2006-006236-22Phase 2Active
- Sponsor
- Azienda Ospedaliera O.I.R.M. - S. Anna
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin in breast cancer (2 arms), sponsored by Azienda Ospedaliera O.I.R.M. - S. Anna. Primary endpoint: Lowest effective metformin dose for testosterone reduction. Started Jun 2010; status: active.
02
Drugs
metformin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-006236-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006236-22.